The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Open accessAbstract
Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of patients treated with CD19-directed chimeric antigen receptor-T cells for B-cell malignancies. Clinical manifestations include headache, confusion, delirium, language disturbance, seizures and rarely, acute cerebral edema. Neurotoxicity is associated with cytokine release syndrome, which occurs in the setting of in-vivo chimeric antigen receptor-T cell activation and proliferation. The mechanisms that lead to neurotoxicity remain unknown, but data from patients and animal models suggest there is compromise of the blood–brain barrier, associated with high levels of cytokines in the blood and cerebrospinal fluid, as well as endothelial activation. Corticosteroids, interleukin-6-targeted therapies, and supportive care are frequently used to manage patients with neurotoxicity, but high-quality evidence of their efficacy is lacking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 4×
“Its potential for treating CRS was considered in light of the high levels of IL-6 observed during CRS and the similarities with macrophage activation syndrome seen in systemic juvenile idiopathic arthritis [22, 76].”
InfluentialLong-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Self-citationBrentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
O’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406
Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0698 · Cited by 1,400
Self-citationTrial of tocilizumab in giant-cell arteritis
Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613849 · Cited by 1,386
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
Atreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272
Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-793141 · Cited by 1,156
Self-citationGardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,121
Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102
Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1319 · Cited by 942
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Le, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0028 · Cited by 873
Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008) · Blood · doi:10.1182/blood-2008-05-155846 · Cited by 795
Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J., Wright, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 764
Ali, S. A., Shi, V., Maric, I., Wang, M., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler-Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 757
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015) · Blood · doi:10.1182/blood-2014-12-580068 · Cited by 727
Lamers, C. H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen, B., Groot, C., Vulto, A., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 704
VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown
Argaw, A. T., Gurfein, B. T., Zhang, Y., Zameer, A., & John, G. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808698106 · Cited by 666
Turtle, C. J., Hay, K. A., Hanafi, L.-A., Li, D., Cherian, S., Chen, X., Wood, B., Lozanski, A., Byrd, J. C., Heimfeld, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.8519 · Cited by 662
Self-citationConsensus Statement on Continuous EEG in Critically Ill Adults and Children, Part I: Indications
Herman, S. T., Abend, N. S., Bleck, T. P., Chapman, K. E., Drislane, F. W., Emerson, R. G., Gerard, E. E., Hahn, C. D., Husain, A. M., Kaplan, P. W., et al. (2015) · Journal of Clinical Neurophysiology · doi:10.1097/wnp.0000000000000166 · Cited by 654
Therapeutic targeting of the angiopoietin–TIE pathway
Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620
Glucocorticoids and the Th1/Th2 Balance
ELENKOV, I. J. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1321.010 · Cited by 612
Chimeric antigen receptor T-cell therapies for lymphoma
Brudno, J. N., & Kochenderfer, J. N. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.128 · Cited by 516
Rosário, C., Zandman-Goddard, G., Meyron-Holtz, E. G., D’Cruz, D. P., & Shoenfeld, Y. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-185 · Cited by 466
Jirik, F. R., Podor, T. J., Hirano, T., Kishimoto, T., Loskutoff, D. J., Carson, D. A., & Lotz, M. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.1.144 · Cited by 459
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers
Zhang, C., Wang, Z., Yang, Z., Wang, M., Li, S., Li, Y., Zhang, R., Xiong, Z., Wei, Z., Shen, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.010 · Cited by 451
Ritchie, D. S., Neeson, P. J., Khot, A., Peinert, S., Tai, T., Tainton, K., Chen, K., Shin, M., Wall, D. M., Hönemann, D., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.154 · Cited by 443
Thistlethwaite, F. C., Gilham, D. E., Guest, R. D., Rothwell, D. G., Pillai, M., Burt, D. J., Byatte, A. J., Kirillova, N., Valle, J. W., Sharma, S. K., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2034-7 · Cited by 406
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
Porter, D., Frey, N., Wood, P. A., Weng, Y., & Grupp, S. A. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0571-y · Cited by 401
Ramos, C. A., Ballard, B., Zhang, H., Dakhova, O., Gee, A. P., Mei, Z., Bilgi, M., Wu, M.-F., Liu, H., Grilley, B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94306 · Cited by 375
Pathogenesis of Brain Edema and Investigation into Anti-Edema Drugs
Michinaga, S., & Koyama, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16059949 · Cited by 339
Wang, C.-M., Wu, Z.-Q., Wang, Y., Guo, Y.-L., Dai, H.-R., Wang, X.-H., Li, X., Zhang, Y.-J., Zhang, W.-Y., Chen, M.-X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1365 · Cited by 332
Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., & Han, W. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5023-8 · Cited by 290
Biomarkers of endothelial activation/dysfunction in infectious diseases
Page, A. V., & Liles, W. C. (2013) · Virulence · doi:10.4161/viru.24530 · Cited by 270
Junghans, R. P., Ma, Q., Rathore, R., Gomes, E. M., Bais, A. J., Lo, A. S. Y., Abedi, M., Davies, R. A., Cabral, H. J., Al‐Homsi, A. S., et al. (2016) · The Prostate · doi:10.1002/pros.23214 · Cited by 267
Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
Taraseviciute, A., Tkachev, V., Ponce, R., Turtle, C. J., Snyder, J. M., Liggitt, H. D., Myerson, D., Gonzalez-Cuyar, L., Baldessari, A., English, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1368 · Cited by 256
Self-citationSurvival in adults with sickle cell disease in a high-income setting
Gardner, K., Douiri, A., Drasar, E., Allman, M., Mwirigi, A., Awogbade, M., & Thein, S. L. (2016) · Blood · doi:10.1182/blood-2016-05-716910 · Cited by 241
Friedman, K. M., Garrett, T. E., Evans, J. W., Horton, H. M., Latimer, H. J., Seidel, S. L., Horvath, C. J., & Morgan, R. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.001 · Cited by 205
Kurzrock, R., Voorhees, P. M., Casper, C., Furman, R. R., Fayad, L., Lonial, S., Borghaei, H., Jagannath, S., Sokol, L., Usmani, S. Z., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3349 · Cited by 205
Chen, F., Teachey, D. T., Pequignot, E., Frey, N., Porter, D., Maude, S. L., Grupp, S. A., June, C. H., Melenhorst, J. J., & Lacey, S. F. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.03.005 · Cited by 195
Locke, F. L., Neelapu, S. S., Bartlett, N. L., Lekakis, L. J., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.1547.1547 · Cited by 184
Reyes, T. M., Fábry, Z., & Coe, C. L. (1999) · Brain Research · doi:10.1016/s0006-8993(99)02189-7 · Cited by 152
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases
Rubbert‐Roth, A., Furst, D. E., Nebesky, J. M., Jin, A., & Berber, E. (2018) · Rheumatology and Therapy · doi:10.1007/s40744-018-0102-x · Cited by 145
Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
Gauthier, J., & Turtle, C. J. (2018) · Current Research in Translational Medicine · doi:10.1016/j.retram.2018.03.003 · Cited by 145
Self-citationDriving CARs on the uneven road of antigen heterogeneity in solid tumors
Chen, N., Li, X., Chintala, N. K., Tano, Z. E., & Adusumilli, P. S. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.002 · Cited by 143
Rochfort, K. D., Collins, L. E., McLoughlin, A., & Cummins, P. M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13408 · Cited by 135
Obstfeld, A. E., Frey, N. V., Mansfield, K. G., Lacey, S. F., June, C. H., Porter, D. L., Melenhorst, J. J., & Wasik, M. A. (2017) · Blood · doi:10.1182/blood-2017-08-802413 · Cited by 134
Venkiteshwaran, A. (2009) · mAbs · doi:10.4161/mabs.1.5.9497 · Cited by 132
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Teachey, D. T., Bishop, M. R., Maloney, D. G., & Grupp, S. A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.19 · Cited by 121
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond
Chang, Z., & Chen, Y. Y. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.002 · Cited by 120
Adoptive T-Cell Therapy for Solid Tumors
Yeku, O., Li, X., & Brentjens, R. J. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_180328 · Cited by 99
The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody
Mihara, M., Nishimoto, N., & Ohsugi, Y. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.5.683 · Cited by 98
Tarp, S., Amarilyo, G., Foeldvari, I., Christensen, R., Woo, J. M. P., Cohen, N., Pope, T. D., & Furst, D. E. (2015) · Rheumatology · doi:10.1093/rheumatology/kev382 · Cited by 84
Grevich, S., & Shenoi, S. (2017) · Adolescent Health Medicine and Therapeutics · doi:10.2147/ahmt.s109495 · Cited by 70
Management of raised intracranial pressure in children with traumatic brain injury
Mohseni-Bod, H., Kukreti, V., & Drake, J. M. (2014) · Journal of Pediatric Neurosciences · doi:10.4103/1817-1745.147572 · Cited by 67
Gardner, R., Leger, K. J., Annesley, C., Summers, C. N., Rivers, J. M., Gust, J., Tarlock, K., Cooper, T. M., Pinto, N. R., Finney, O. C., et al. (2016) · Blood · doi:10.1182/blood.v128.22.586.586 · Cited by 65
Self-citationAcute Disseminated Encephalomyelitis, Transverse Myelitis, and Neuromyelitis Optica
Wingerchuk, D. M., & Weinshenker, B. G. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000433289.38339.a2 · Cited by 64
Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice
Pennell, C. A., Barnum, J. L., McDonald-Hyman, C. S., Panoskaltsis‐Mortari, A., Riddle, M. J., Xiong, Z., Loschi, M. L., Thangavelu, G., Campbell, H. M., Storlie, M. D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.006 · Cited by 59
Curtis, J., Perez-Gutthann, S., Suissa, S., Napalkov, P., Singh, N., Thompson, L., & Porter-Brown, B. (2015) · Seminars in Arthritis & Rheumatism · doi:10.1016/j.semarthrit.2014.07.006 · Cited by 53
Acute Multiple Sclerosis Relapse
Berkovich, R. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000330 · Cited by 52
The Evolution and Future of CAR T Cells for B‐Cell Acute Lymphoblastic Leukemia
Annesley, C., Summers, C. N., Ceppi, F., & Gardner, R. A. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.950 · Cited by 36
Carvajal, R., Sato, T., Shoushtari, A., Sacco, J., Nathan, P., Orloff, M., Corrie, P., Steven, N., Evans, J., Infante, J., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0289-3 · Cited by 34
Shah, B. D., Huynh, V., Sender, L. S., Lee, D. W., Castro, J. E., Wierda, W. G., Dietz, A. C., Schiller, G. J., Kersten, M. J., Handgretinger, R., et al. (2016) · Blood · doi:10.1182/blood.v128.22.2803.2803 · Cited by 29
Beginning the CAR T cell therapy revolution in the US and EU
Grupp, S. A. (2018) · Current Research in Translational Medicine · doi:10.1016/j.retram.2018.03.004 · Cited by 29
Santomasso, B., Park, J. H., Rivière, I., Mead, E., Halton, E. F., Diamonte, C., Purdon, T. J., Sénéchal, B., Li, D., Sadelain, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3019 · Cited by 22
Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia
Prudent, V., & BREITBART, W. S. (2017) · Palliative & Supportive Care · doi:10.1017/s147895151600095x · Cited by 18
Cited by
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms
Huang, X., Hussain, B., & Chang, J. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13569 · Cited by 709
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Schubert, M.-L., Schmitt, M., Wang, L., Ramos, C. A., Jordan, K., Müller-Tidow, C., & Dreger, P. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.478 · Cited by 491
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 396
Understanding and treating the inflammatory adverse events of cancer immunotherapy
Dougan, M., Luoma, A. M., Dougan, S. K., & Wucherpfennig, K. W. (2021) · Cell · doi:10.1016/j.cell.2021.02.011 · Cited by 319
“Interestingly, rates of neurotoxicity appear to be lower for CAR T cell therapies that do not target the CD19 antigen, although neurotoxicity has also been observed with CAR T cells specific for other antigens (Gust et al., 2018).”
Metadata
- Authors
- Gust, J., Taraseviciute, A., & Turtle, C. J.
- Venue
- CNS Drugs
- Published
- 2018-11-01
- Volume
- 32
- Issue
- 12
- Pages
- 1091-1101
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2899385155
- Cited by
- 264
- References
- 85
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.